In vitro activity of omadacycline against geographically diverse rapidly growing nontuberculous mycobacteria (NTM) clinical isolates

IF 2.1 4区医学 Q3 INFECTIOUS DISEASES

Diagnostic microbiology and infectious disease Pub Date : 2024-12-27 DOI:10.1016/j.diagmicrobio.2024.116663

Eva Terschlüsen , Akio Aono , Diane M. Anastasiou , Alisa W. Serio , Satoshi Mitarai , Jakko van Ingen

{"title":"In vitro activity of omadacycline against geographically diverse rapidly growing nontuberculous mycobacteria (NTM) clinical isolates","authors":"Eva Terschlüsen , Akio Aono , Diane M. Anastasiou , Alisa W. Serio , Satoshi Mitarai , Jakko van Ingen","doi":"10.1016/j.diagmicrobio.2024.116663","DOIUrl":null,"url":null,"abstract":"<div><div>Nontuberculous mycobacteria (NTM) are emerging opportunistic pathogens with limited treatment options due to resistance to multiple antibiotic classes. This study aimed to evaluate the <em>in vitro</em> activity of omadacycline and comparator antibiotics against rapidly growing mycobacteria (RGM) clinical isolates. Minimum inhibitory concentration (MIC) evaluation of RGM clinical isolates was performed by two independent laboratories (EU and Japan). A total of 383 isolates (211 EU, 172 Japan) were evaluated. Omadacycline was active against all RGM species tested. For <em>Mycobacterium abscessus</em> subsp. <em>abscessus</em>, MIC<sub>50</sub> and MIC<sub>90</sub> values (read at 100 % inhibition) were 1 and 4 µg/mL (EU) and 0.5 and 1 µg/mL (Japan), respectively. <em>Mycobacterium fortuitum</em> and <em>Mycobacterium chelonae</em> both had MIC<sub>90</sub> values of 0.5 µg/mL (Japan). Omadacycline has consistent, potent <em>in vitro</em> activity against RGM clinical isolates from 15 geographically diverse countries, and thus warrants additional studies and continued development of omadacycline as a potential treatment option for NTM-related disease.</div></div>","PeriodicalId":11329,"journal":{"name":"Diagnostic microbiology and infectious disease","volume":"111 3","pages":"Article 116663"},"PeriodicalIF":2.1000,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diagnostic microbiology and infectious disease","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0732889324004875","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Nontuberculous mycobacteria (NTM) are emerging opportunistic pathogens with limited treatment options due to resistance to multiple antibiotic classes. This study aimed to evaluate the in vitro activity of omadacycline and comparator antibiotics against rapidly growing mycobacteria (RGM) clinical isolates. Minimum inhibitory concentration (MIC) evaluation of RGM clinical isolates was performed by two independent laboratories (EU and Japan). A total of 383 isolates (211 EU, 172 Japan) were evaluated. Omadacycline was active against all RGM species tested. For Mycobacterium abscessus subsp. abscessus, MIC₅₀ and MIC₉₀ values (read at 100 % inhibition) were 1 and 4 µg/mL (EU) and 0.5 and 1 µg/mL (Japan), respectively. Mycobacterium fortuitum and Mycobacterium chelonae both had MIC₉₀ values of 0.5 µg/mL (Japan). Omadacycline has consistent, potent in vitro activity against RGM clinical isolates from 15 geographically diverse countries, and thus warrants additional studies and continued development of omadacycline as a potential treatment option for NTM-related disease.

查看原文本刊更多论文

奥马他环素对不同地域快速生长的非结核分枝杆菌（NTM）临床分离株的体外活性。

非结核分枝杆菌（NTM）是新兴的机会性病原体，由于对多种抗生素的耐药性，治疗选择有限。本研究旨在评价奥马达环素和比较抗生素对临床分离的快速生长分枝杆菌（RGM）的体外活性。RGM临床分离株的最低抑菌浓度（MIC）评估由欧盟和日本两个独立实验室进行。共分离383株，其中欧盟211株，日本172株。奥马达环素对所有RGM品种均有抑制作用。对于脓肿分枝杆菌亚种。在脓肿菌中，MIC50和MIC90值（100%抑制时读取）分别为1和4µg/mL（欧盟）和0.5和1µg/mL（日本）。福氏分枝杆菌和龟分枝杆菌MIC90值均为0.5µg/mL（日本）。奥马达环素对来自15个地理位置不同的国家的RGM临床分离株具有一致、有效的体外活性，因此值得进一步研究和继续开发奥马达环素作为ntm相关疾病的潜在治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diagnostic microbiology and infectious disease 医学-传染病学

CiteScore

5.30

自引率

3.40%

发文量

149

审稿时长

56 days

期刊介绍： Diagnostic Microbiology and Infectious Disease keeps you informed of the latest developments in clinical microbiology and the diagnosis and treatment of infectious diseases. Packed with rigorously peer-reviewed articles and studies in bacteriology, immunology, immunoserology, infectious diseases, mycology, parasitology, and virology, the journal examines new procedures, unusual cases, controversial issues, and important new literature. Diagnostic Microbiology and Infectious Disease distinguished independent editorial board, consisting of experts from many medical specialties, ensures you extensive and authoritative coverage.